Patent: 10,251,883
✉ Email this page to a colleague
Summary for Patent: 10,251,883
| Title: | Methods and formulations for modulating Lyn kinase activity and treating related disorders |
| Abstract: | The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence. |
| Inventor(s): | Reaume; Andrew G. (Exton, PA), Saporito; Michael S. (Exton, PA) |
| Assignee: | Melior Pharmaceuticals I, Inc. (Exton, PA) |
| Application Number: | 15/684,130 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,251,883
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2025-08-22 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
